Lumerical Solutions - a provider of photonic design software - has announced its 2013b release, which provides significant improvements to all of Lumericals products
Lumerical Solutions has announced the release of FDTD Solutions 8.0, the nanophotonic design environment based on the finite-difference time-domain (FDTD) technique
Lumerical Solutions has released FDTD Solutions 7.5 which features a concurrent computing capability allowing users to distribute simulations on multiple independent computer resources
Vancouver-based Lumerical Solutions, a global provider of nanophotonic design software, has unveiled a number of improvements to its flagship product, FDTD Solutions 7.0
Lumerical Solutions, a provider of nanophotonic design software, has announced the availability of Mode Solutions Release 4.0, incorporating the company's Conformal Mesh Technology and support for Mac OS X
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
